Newsroom

August 12, 2026

NAPLES, Fla., August 12, 2026 — Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL)-associated amyloidosis, a rare, progressive,...

☀️ Our latest Summer Newsletter is here!

Catch up on the latest Amyloidosis Foundation news, upcoming events, and ways you can get involved. We hope you’ll take a few minutes to check it out and stay connected with everything happening this summer!

Click HERE to read the newsletter.

– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –

– CR rate now 95% (19 of 20 patients) –

– All CRs reached within 1 year of follow-up post-dosing –

– No relapses to-date observed for patients who have reached CR –

– All subsequently enrolled patients for...

NAPLES, Fla., June 4, 2026— Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for zamubafusp alfa (AT-02) for the treatment of light chain (AL) amyloidosis, a rare, progressive, debilitating, and often fatal condition.

Zamubafusp...

– Of first 20 patients, all four MRD-negative patients have converted to complete response (CR) –

– CR rate now 95% (19 of 20 patients) –

– All CRs reached within 1 year of follow-up post-dosing –

– No relapses to-date observed for patients who have reached CR –

– All subsequently enrolled patients for...